Perrigo receives final approval from FDA for OTC equivalent of Mucinex DM

Perrigo Company asserted that it has received final approval from the U.S Food and Drug Administration for the store brand OTC equivalent of Muciinex DM Maximum Strength Guaifenesin and Dextromethorphan Hydrobromide Extended-Release Tablets, 1200 mg/60 mg).

This product is set to be packaged and marketed as a store brand or retailer  ‘own label’ brand and will provide consumers with a high-quality, value alternative to Mucinex DM Maximum Strength.

Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Retail sales of Mucinex DM Maximum Strength for the last 12 months were approximately $128 million as measured by IRI.

Perrigo Executive Vice President and President, Consumer Healthcare Americas Jeff Needham stated, “This final approval and upcoming launch is an important accomplishment for our OTC business. Key product launches like Perrigo’s store brand equivalent of Mucinex DM Maximum Strength provide our customers and consumers with high quality, value alternatives in important treatment categories.”